848 related articles for article (PubMed ID: 27088403)
1. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience.
Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N
Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403
[TBL] [Abstract][Full Text] [Related]
2. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
[TBL] [Abstract][Full Text] [Related]
3. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy.
Minami Y; Kajimoto K; Terajima Y; Yashiro B; Okayama D; Haruki S; Nakajima T; Kawashiro N; Kawana M; Hagiwara N
J Am Coll Cardiol; 2011 Jun; 57(23):2346-55. PubMed ID: 21636036
[TBL] [Abstract][Full Text] [Related]
5. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.
McLeod CJ; Ommen SR; Ackerman MJ; Weivoda PL; Shen WK; Dearani JA; Schaff HV; Tajik AJ; Gersh BJ
Eur Heart J; 2007 Nov; 28(21):2583-8. PubMed ID: 17483110
[TBL] [Abstract][Full Text] [Related]
6. [Hypertrophic cardiomyopathy with midventricular obstruction of the left ventricle (MVO)--case report].
Pizoń T; Rajzer M; Wojciechowska W; Jastrzebski M; Olszanecka A; Rojek M; Jurczyszyn A; Czarnecka D
Przegl Lek; 2015; 72(5):271-5. PubMed ID: 26817332
[TBL] [Abstract][Full Text] [Related]
7. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
[TBL] [Abstract][Full Text] [Related]
8. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
[TBL] [Abstract][Full Text] [Related]
9. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
10. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
[TBL] [Abstract][Full Text] [Related]
11. [Prevention of sudden death in hypertrophic cardiomyopathy (HCM ): implanted defibrillators in HCM].
Maron BJ; Spirito P
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):297-302. PubMed ID: 19791462
[TBL] [Abstract][Full Text] [Related]
12. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: An international multicenter study.
Balaji S; DiLorenzo MP; Fish FA; Etheridge SP; Aziz PF; Russell MW; Tisma S; Pflaumer A; Sreeram N; Kubus P; Law IH; Kantoch MJ; Kertesz NJ; Strieper M; Erickson CC; Moore JP; Nakano SJ; Singh HR; Chang P; Cohen M; Fournier A; Ilina MV; Smith RT; Zimmerman F; Horndasch M; Li W; Batra A; Liberman L; Hamilton R; Janson CM; Sanatani S; Zeltser I; McDaniel G; Blaufox AD; Garnreiter JM; Katcoff H; Shah M
Heart Rhythm; 2019 Oct; 16(10):1462-1467. PubMed ID: 31026510
[TBL] [Abstract][Full Text] [Related]
14. Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy.
Konstantinou DM; Efthimiadis GK; Vassilikos V; Paraskevaidis S; Pagourelias E; Maron BJ; Karvounis H
J Cardiovasc Med (Hagerstown); 2016 Jun; 17(6):433-9. PubMed ID: 26885981
[TBL] [Abstract][Full Text] [Related]
15. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Begley DA; Mohiddin SA; Tripodi D; Winkler JB; Fananapazir L
Pacing Clin Electrophysiol; 2003 Sep; 26(9):1887-96. PubMed ID: 12930505
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.
Ruiz-Salas A; García-Pinilla JM; Cabrera-Bueno F; Fernández-Pastor J; Peña-Hernández J; Medina-Palomo C; Barrera-Cordero A; De Teresa E; Alzueta J
Europace; 2016 May; 18(5):773-7. PubMed ID: 25855675
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
[TBL] [Abstract][Full Text] [Related]
19. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
[TBL] [Abstract][Full Text] [Related]
20. Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.
Rigopoulos AG; Daci S; Pfeiffer B; Papadopoulou K; Neugebauer A; Seggewiss H
Clin Res Cardiol; 2016 Nov; 105(11):953-961. PubMed ID: 27270758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
